- Home
- HTBI vs MLYS Comparison
HTBI vs MLYS Comparison
Compare HTBI & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTBI
- MLYS
- Stock Information
- Founded
- HTBI 1926
- MLYS 2019
- Country
- HTBI United States
- MLYS United States
- Employees
- HTBI N/A
- MLYS N/A
- Industry
- HTBI Savings Institutions
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- HTBI Finance
- MLYS Health Care
- Exchange
- HTBI Nasdaq
- MLYS Nasdaq
- Market Cap
- HTBI 641.9M
- MLYS 634.6M
- IPO Year
- HTBI 2012
- MLYS 2023
- Fundamental
- Price
- HTBI $31.66
- MLYS $9.24
- Analyst Decision
- HTBI Buy
- MLYS Strong Buy
- Analyst Count
- HTBI 4
- MLYS 2
- Target Price
- HTBI $39.00
- MLYS $30.00
- AVG Volume (30 Days)
- HTBI 33.4K
- MLYS 217.3K
- Earning Date
- HTBI 01-22-2025
- MLYS 11-11-2024
- Dividend Yield
- HTBI 1.52%
- MLYS N/A
- EPS Growth
- HTBI 14.18
- MLYS N/A
- EPS
- HTBI 3.52
- MLYS N/A
- Revenue
- HTBI $187,440,000.00
- MLYS N/A
- Revenue This Year
- HTBI N/A
- MLYS N/A
- Revenue Next Year
- HTBI N/A
- MLYS N/A
- P/E Ratio
- HTBI $8.98
- MLYS N/A
- Revenue Growth
- HTBI 2.84
- MLYS N/A
- 52 Week Low
- HTBI $23.55
- MLYS $7.95
- 52 Week High
- HTBI $38.99
- MLYS $16.91
- Technical
- Relative Strength Index (RSI)
- HTBI 26.68
- MLYS 27.24
- Support Level
- HTBI $32.80
- MLYS $12.00
- Resistance Level
- HTBI $33.74
- MLYS $13.37
- Average True Range (ATR)
- HTBI 0.78
- MLYS 0.92
- MACD
- HTBI -0.23
- MLYS -0.31
- Stochastic Oscillator
- HTBI 16.43
- MLYS 0.67
About HTBI HomeTrust Bancshares Inc.
HomeTrust Bancshares Inc operates as a bank holding company. It engaged in the business of planning, directing and coordinating the business activities of the Bank. The Bank is a North Carolina state chartered bank and provides a range of retail and commercial banking products.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.